Scientists resurrect ancient cannabis enzymes with medical promise

Researchers at Wageningen University & Research have recreated enzymes from cannabis ancestors millions of years old, revealing how the plant evolved to produce compounds like THC, CBD, and CBC. These ancient enzymes, more flexible than modern versions, show potential for easier biotechnological production of cannabinoids for medical use. The findings, published in Plant Biotechnology Journal, could lead to new medicinal cannabis varieties.

Cannabis plants today produce key cannabinoids—THC, CBD, and CBC—using specialized enzymes, each dedicated to a single compound. A study from Wageningen University & Research demonstrates that this precision emerged through evolution. Early ancestors of cannabis possessed more versatile enzymes capable of generating multiple cannabinoids simultaneously.

To trace this development, the team employed ancestral sequence reconstruction, analyzing DNA from modern plants to predict and rebuild enzymes active millions of years ago. These resurrected enzymes were then synthesized in the lab and tested, providing the first experimental evidence of how cannabinoid biosynthesis originated in a recent cannabis ancestor and refined over time through gene duplications.

The research uncovered practical advantages: the ancient enzymes proved more robust and easier to express in microorganisms like yeast compared to contemporary ones. This could streamline biotechnological manufacturing of cannabinoids, which are increasingly produced outside plants for medical applications.

"What once seemed evolutionarily 'unfinished' turns out to be highly useful," noted lead researcher Robin van Velzen, who collaborated with Cloé Villard. "These ancestral enzymes are more robust and flexible than their descendants, which makes them very attractive starting points for new applications in biotechnology and pharmaceutical research."

Particularly promising is an ancient enzyme that specifically produces CBC, known for anti-inflammatory and analgesic effects. No current cannabis variety naturally yields high CBC levels, so integrating this enzyme could create innovative medicinal strains. The study, detailed in Plant Biotechnology Journal (DOI: 10.1111/pbi.70475), bridges evolutionary biology with potential health benefits.

관련 기사

Lab illustration showing CBD and THC compounds targeting and slowing ovarian cancer cells while sparing healthy ones.
AI에 의해 생성된 이미지

Cannabis compounds CBD and THC show targeted effects against ovarian cancer cells in lab study

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

Laboratory research led by scientists at Khon Kaen University indicates that cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), two key cannabis compounds, can slow the growth and spread of ovarian cancer cells in vitro, particularly when used together in a 1:1 ratio, while causing relatively limited damage to healthy cells. The early-stage findings, reported in Frontiers in Pharmacology, suggest a potential avenue for future ovarian cancer treatments but are far from clinical use.

Scientists at UBC Okanagan have identified the enzymes plants use to produce mitraphylline, a rare compound with potential anti-cancer properties. This breakthrough solves a long-standing mystery and paves the way for sustainable production of such molecules. The discovery highlights plants' untapped potential in medicine.

AI에 의해 보고됨

Scientists at the Weizmann Institute of Science in Israel have modified tobacco plants to produce five powerful psychedelic compounds typically found in mushrooms, plants, and toads. The technique uses temporary genetic changes to create a sustainable source for research and potential medicines. Experts say this could simplify production compared to chemical synthesis or harvesting from nature.

In the latest assessment following prior reviews like the 2025 Annals analysis showing limited THC benefits, a Cochrane review finds cannabis-based medicines offer no clinically meaningful relief for chronic neuropathic pain versus placebo. Analyzing 21 randomized trials with over 2,100 adults, it reports no high-quality evidence of effectiveness, with only minor, insignificant improvements from THC-CBD combinations.

AI에 의해 보고됨

Researchers at Shandong University have modified the probiotic bacterium Escherichia coli Nissle 1917 to produce the anticancer drug Romidepsin directly in tumors. In mouse models of breast cancer, the engineered bacteria accumulated in tumors and released the drug. The findings were published on March 17 in PLOS Biology.

Researchers at the University of Waterloo have developed engineered bacteria designed to invade and eat solid tumors from the inside out. The approach uses microbes that thrive in oxygen-free environments, targeting the low-oxygen cores of tumors. A genetic modification allows the bacteria to survive near oxygenated edges, controlled by a quorum-sensing mechanism.

AI에 의해 보고됨

Researchers have discovered genes that duplicated before the last universal common ancestor of all life, offering insights into evolution's earliest stages. These universal paralogs, present in nearly every organism, suggest protein production and membrane transport were among the first biological functions. The findings, published in Cell Genomics, highlight how ancient genetic patterns can reveal pre-LUCA history.

 

 

 

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부